NCT02529930 2022-07-13An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)Nykode Therapeutics ASAPhase 1/2 Completed34 enrolled